high5immunology.tv | IBD | ECCO 2024

Targeting safety

ENG

PIZZICATO

ECCO 2024

Are all JAKies the same?

F. Gomollón, A. Dignaß, S. Schreiber, G. Mantzaris, F. Magro

ENG

ENEIDA registry of GETECCU

ECCO 2024

The quest for predictive markers goes on...

F. Gomollón, A. Dignaß, S. Schreiber, G. Mantzaris, F. Magro

ENG

True North

ECCO 2024

S1P-Modulators from a safety perspective

F. Gomollón, A. Dignaß, S. Schreiber, G. Mantzaris, F. Magro

ENG

ECCO 2024

Real-world data from a H2H-study on Vedolizumab vs.…

F. Gomollón, A. Dignaß, S. Schreiber, G. Mantzaris, F. Magro

ENG

International PSC Registry (IPSCR)

ECCO 2024

Primary sclerosing cholangitis – lessons from a large…

F. Gomollón, A. Dignaß, S. Schreiber, G. Mantzaris, F. Magro

Therapeutic concepts

ENG

PROFILE

ECCO 2024

A spotlight on the PROFILE study

I. Dotan, G. Rogler, S. Schreiber, M. Allez, D. Laharie, J. Lindsay, A. Dignaß, P. Eder

ENG

ADMIRE-CD II, INSPIRE

ECCO 2024

Cell-based therapies: The end of the story or the…

I. Dotan, G. Rogler, S. Schreiber, M. Allez, D. Laharie, J. Lindsay, A. Dignaß, P. Eder

ENG

VEGA-Study

ECCO 2024

Combination of different drug classes - risks and…

I. Dotan, G. Rogler, S. Schreiber, M. Allez, D. Laharie, J. Lindsay, A. Dignaß, P. Eder

ENG

ECCO 2024

Treatment targets in 2024 - a silent revolution

I. Dotan, G. Rogler, S. Schreiber, M. Allez, D. Laharie, A. Dignaß, P. Eder

ENG

SPICY-trial

ECCO 2024

Finally here: controlled trials in surgery!

I. Dotan, G. Rogler, S. Schreiber, M. Allez, D. Laharie, J. Lindsay, A. Dignaß, P. Eder

Targeting efficacy

ENG

VIVID-1

ECCO 2024

Mirikizumab in CD

P. Irving, A. Moschen, A. Dignaß, A. Armuzzi, M. Fantini, S. Schreiber

ENG

COMMAND, INSPIRE

ECCO 2024

IL-23 in UC

P. Irving, A. Moschen, A. Dignaß, A. Armuzzi, M. Fantini, S. Schreiber

ENG

VIVID-1, SEQUENCE

ECCO 2024

Ustekinumab first, anti-p19 second?

P. Irving, A. Moschen, A. Dignaß, A. Armuzzi, M. Fantini, S. Schreiber

ENG

True North, PIZZICATO

ECCO 2024

Next chapter in S1P- and JAK-inhibition

P. Irving, A. Moschen, A. Dignaß, A. Armuzzi, M. Fantini, S. Schreiber

ENG

ECCO 2024

Obefazimod & IL23R-CAR-Tregs - new molecules in focus

P. Irving, A. Moschen, A. Dignaß, A. Armuzzi, M. Fantini, S. Schreiber, S. Danese

Targeting efficacy in CD

ENG

PIZZICATO

ECCO 2024

Results of the phase II PIZZICATO (ritlecitinib &…

Séverine Vermeire, MD, PhD

ENG

VIVID 1

ECCO 2024

VIVID 1: Mirikizumab in Crohn's Disease

James Lindsay, MD, PhD

ENG

PROFILE

ECCO 2024

Changing the PROFILE of how we treat CD

Peter Irving, MD

ENG

VIVID-1

ECCO 2024

VIVID 1: Comparison of mirikizumab with ustekinumab in…

Fernando Magro, MD, PhD

ENG

VIVID-1

ECCO 2024

Mirikizumab vs Ustekinumab

Silvio Danese, MD, PhD

ENG

VIVID-1

ECCO 2024

Mirikizumab in crohn's disease

Axel Dignaß, MD, PhD

ENG

ADMIRE-CD II

ECCO 2024

Darvadstrocel for complex perianal fistulas and Crohn’s…

James Lindsay, MD, PhD

ENG

VIVID-1

ECCO 2024

Mirikizumab in moderate to severe Crohn’s disease:…

Gerassimos Mantzaris, MD

ENG

PIZZICATO

ECCO 2024

PIZZICATO - new JAKies for crohn's disease

Alexander Moschen, MD, PhD

ENG

ECCO 2024

Tregs - a treatment for the future?

Peter Irving, MD

Targeting efficacy in CD multilanguage

POR

VIVID-1

ECCO 2024

VIVID 1- Comparação do Mirikizumab com o Ustecinumab na…

Fernando Magro, MD, PhD

AUT

PIZZICATO

ECCO 2024

PIZZICATO - neue JAKs für Morbus Crohn

Alexander Moschen, MD, PhD

GER

VIVID-1

ECCO 2024

Mirikizumab bei Morbus Crohn

Axel Dignaß, MD, PhD

NED

PIZZICATO

ECCO 2024

Resultaten van de fase 2 PIZZICATO (ritlecitinib &…

Séverine Vermeire, MD, PhD

ITA

VIVID-1

ECCO 2024

Mirikizumab vs Ustekinumab

Silvio Danese, MD, PhD

GRE

VIVID-1

ECCO 2024

Mirikizumab στη θεραπεία της μέτριας προς βαρειά NC:…

Gerassimos Mantzaris, MD

Targeting efficacy in UC

ENG

ECCO 2024

VTX002 (S1P-modulator) & obefazimod in ulcerative…

Axel Dignaß, MD, PhD

ENG

COMMAND, QUASAR

ECCO 2024

Risankizumab & guselkumab in ulcerative colitis

Axel Dignaß, MD, PhD

ENG

ECCO 2023

VTX-002 in patients with moderate to severe UC

Silvio Danese, MD, PhD

ENG

LUCENT-1 & -2

ECCO 2024

Mirikizumab in anti-TNF failures with UC

Peter Irving, MD

ENG

CONFER project

ECCO 2024

The efficacy of biologics and small molecules in…

Piotr Eder, MD

ENG

ECCO 2024

Long term outcome of Obefazimod in UC

Séverine Vermeire, MD, PhD

Targeting efficacy in UC multilanguage

GER

ECCO 2024

VTX002 (S1P-Modulator) & Obefazimod bei Colitis…

Axel Dignaß, MD, PhD

POL

CONFER project

ECCO 2024

Leki biologiczne i małocząsteczkowe w terapii…

Piotr Eder, MD

GER

COMMAND, QUASAR

ECCO 2024

Risankizumab & Guselkumab bei Colitis Ulcerosa

Axel Dignaß, MD, PhD

ITA

ECCO 2024

VTX-002 in pazienti con colite ulcerosa da moderata a…

Silvio Danese, MD, PhD

NED

ECCO 2024

lange-termijns uitkomst van obefazimod in UC

Séverine Vermeire, MD, PhD

Targeting efficacy IBD

ENG

E-QUALITY

ECCO 2024

Still a long road ahead in standards of care in IBD –…

Piotr Eder, MD

ENG

PROFILE, COMMAND SEQUENCE, VIVID-1

ECCO 2024

Therapy in transition

Stefan Schreiber, MD

ENG

ECCO 2024

Comparability examination between SB17 and Ustekimumab…

Alessandro Armuzzi, MD, PhD

Targeting efficacy IBD multilanguage

GER

PROFILE, COMMAND SEQUENCE, VIVID-1

ECCO 2024

Therapie im Umbruch

Stefan Schreiber, MD

POL

E-QUALITY

ECCO 2024

Marzenia a rzeczywistość – wyniki ankiety E-QUALITY na…

Piotr Eder, MD

ITA

ECCO 2024

Esame di comparabilità tra SP17 e ustekimumab…

Alessandro Armuzzi, MD, PhD

Therapeutic concepts in CD

ENG

PROFILE

ECCO 2024

PROFILE: Biomarkers not successfull for therapy…

Gerhard Rogler, MD, PhD

ENG

PROFILE

ECCO 2024

PROFILE: practice-changing results

James Lindsay, MD, PhD

ENG

ENEIDA registry of GETECCU

ECCO 2024

Biomarker for biological loss of response in CD?

Iris Dotan, MD

ENG

PROFILE

ECCO 2024

Results from the PROFILE-trial

Massimo Claudio Fantini, MD, PhD

ENG

ADMIRE-CD II

ECCO 2024

Allogenic mesenchymal stem cells for complex fistula in…

Matthieu Allez, MD, PhD

ENG

ECCO 2024

Should we proactively treat CD-patients having small…

David Laharie, MD, PhD

ENG

PROFILE

ECCO 2024

Early intervention in Crohn´s disease therapy

Fernando Magro, MD, PhD

ENG

PROFILE

ECCO 2024

Changing treatment paradigm in CD

Alessandro Armuzzi, MD, PhD

Therapeutic concepts in CD multilanguage

FRA

ECCO 2024

Faut-il traiter les patients avec les lesions de Crohn…

David Laharie, MD, PhD

ITA

PROFILE

ECCO 2024

Cambiano i paradigmi di trattamento nelle malattie di…

Alessandro Armuzzi, MD, PhD

GER

ECCO 2024

PROFILE: Biomarker nicht erfolgreich zur Prädiktion der…

Gerhard Rogler, MD, PhD

FRA

ADMIRE-CD II

ECCO 2024

Injection de cellules souches mesenchimateuses…

Matthieu Allez, MD, PhD

ISR

ENEIDA registry of GETECCU

ECCO 2024

Biomarker for biological loss of response in CD?

Iris Dotan, MD

ITA

PROFILE

ECCO 2024

Risultati dallo studio PROFILE

Massimo Claudio Fantini, MD, PhD

POR

PROFILE

ECCO 2024

Intervenção terapêutica precoce na doença de Crohn

Fernando Magro, MD, PhD

Therapeutic concepts in UC

ENG

VEGA-Study

ECCO 2024

Guselkumab & Golimumab have complementary effects when…

Matthieu Allez, MD, PhD

ENG

ACTIVE

ECCO 2024

Towards the proactive management of AS-UC responding to…

David Laharie, MD, PhD

Therapeutic concepts in UC multilanguage

FRA

ACTIVE

ECCO 2024

Vers un traitement plus agressif de la colite aigüe…

David Laharie, MD, PhD

FRA

VEGA-Study

ECCO 2024

Guselkumab & Golimumab ont des effets complémentaires…

Matthieu Allez, MD, PhD

Therapeutic concepts IBD

ENG

ECCO 2024

Use of CAR-Tregs in IBD: preclinical data

Massimo Claudio Fantini, MD, PhD

ENG

HELIOS trial

ECCO 2024

HD-WLE with segmental reinspection is not inferior to…

Gerassimos Mantzaris, MD

ENG

ECCO 2024

Personalized treatment in IBD: reality or hype?

Séverine Vermeire, MD, PhD

ENG

ECCO 2024

Immunohomeostasis by regulatory CAR-T cells!?

Alexander Moschen, MD, PhD

ENG

PROFILE, COMMAND SEQUENCE, VIVID-1

ECCO 2024

Therapy in transition

Stefan Schreiber, MD

Therapeutic concepts IBD multilanguage

GRE

HELIOS trial

ECCO 2024

HD-WLE με επανεξέταση των τμημάτων δεν υπολείπεται της…

Gerassimos Mantzaris, MD

GER

PROFILE, COMMAND SEQUENCE, VIVID-1

ECCO 2024

Therapie im Umbruch

Stefan Schreiber, MD

AUT

ECCO 2024

Immunohomöstase durch regulatorische CAR-T-Zellen!?

Alexander Moschen, MD, PhD

ITA

ECCO 2024

Utilizzo di cellule CAR Tregs nelle MICI: dati…

Massimo Claudio Fantini, MD, PhD

NED

ECCO 2024

gepersonaliseerde aanpak van IBD: realiteit of hype?

Séverine Vermeire, MD, PhD

Surgery in IBD

ENG

ECCO 2024

End of the Kono-S legend!

David Laharie, MD, PhD

ENG

ECCO 2024

No changes to surgical techniques for ileosecal…

James Lindsay, MD, PhD

ENG

ECCO 2024

Implication of proctocolectomy in patients affected by…

Massimo Claudio Fantini, MD, PhD

ENG

International PSC Registry (IPSCR)

ECCO 2024

Colectomy and the natural history of PSC – lessons form…

Piotr Eder, MD

ENG

Miracle-Project

ECCO 2024

MIRACLE project: Avoidance of protective Ileostomy

Gerhard Rogler, MD, PhD

ENG

ADMIRE-CD II

ECCO 2024

Randomised clinical trials finally coming to IBD…

Fernando Gomollón, MD

ENG

SPICY

ECCO 2024

Extended mesenterectomy is not superior to mesenteric…

Gerassimos Mantzaris, MD

Surgery in IBD multilanguage

GRE

SPICY

ECCO 2024

Η εκτεταμένη εκτομή του μεσεντερίου δεν υπερέχει της…

Gerassimos Mantzaris, MD

ITA

ECCO 2024

Implicazioni della proctocolectomia in pazienti affetti…

Massimo Claudio Fantini, MD, PhD

GER

MIRACLE-Projekt

ECCO 2024

MIRACLE-Projekt: Verzicht auf protektive Ileostomie

Gerhard Rogler, MD, PhD

FRA

ECCO 2024

La fin de la legende du Kono-S!

David Laharie, MD, PhD

POL

International PSC Registry (IPSCR)

ECCO 2024

Kolektomia a historia naturalna PSC – czy istnieje…

Piotr Eder, MD

ESP

ADMIRE-CD II

ECCO 2024

Los ensayos clínicos aleatorizados llegan a la cirugía…

Fernando Gomollón, MD

New treatment goals IBD

ENG

ECCO 2024

Molecular healing, our next goal?

Fernando Gomollón, MD

New treatment goals IBD multilanguage

ESP

ECCO 2024

Cicatrización molecular: nuestro próximo objetivo?

Fernando Gomollón, MD

Basic Science

ENG

SELECTION

ECCO 2024

Transcriptomic profiles in patients with UC receiving…

Fernando Magro, MD, PhD

ENG

ECCO 2024

Molecular effects of IL-23p19 blockade

Alexander Moschen, MD, PhD

Basic Science multilanguage

GER

ECCO 2024

Molekulare Effekte der IL-23p19-Blockade

Alexander Moschen, MD, PhD

POR

SELECTION

ECCO 2024

Análise do Transcriptoma em doentes com colite ulcerosa…

Fernando Magro, MD, PhD

Nutrition in IBD

ENG

ECCO 2024

Diet & Lifestyle: Keys for the management of IBD!

Iris Dotan, MD

Nutrition in IBD multilanguage

ISR

ECCO 2024

Diet & Lifestyle: Keys for the management of IBD!

Iris Dotan, MD